Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 4, 2019
- Accepted in final form June 25, 2019
- First Published August 16, 2019.
Author Disclosures
- Helena Stengel,
- Atay Vural, MD, PhD,
- Anna-Michelle Brunder,
- Annika Heinius,
- Luise Appeltshauser, MD,
- Bianca Fiebig,
- Florian Giese, MD,
- Christian Dresel, MD,
- Aikaterini Papagianni, MD,
- Frank Birklein, MD, PhD,
- Joachim Weis, MD,
- Tessa Huchtemann, MD,
- Christian Schmidt, MD,
- Peter Körtvelyessy, MD,
- Carmen Villmann, PhD,
- Edgar Meinl, MD,
- Claudia Sommer, MD, PhD,
- Frank Leypoldt, MD* and
- Kathrin Doppler, MD*
- Helena Stengel,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Atay Vural, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) The Scientific and Technological Research Council of Turkey (TUBITAK), Postdoctoral research fellowship program 2219, 2015-2016
NONE
(1) European Academy of Neurology, Research Fellowship, 2015- 2016 (2) Alexander von Humboldt Foundation, Georg-Forster Experienced Researcher Fellowship, 2017-2018
NONE
NONE
NONE
NONE
NONE
NONE
- Anna-Michelle Brunder,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annika Heinius,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luise Appeltshauser, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bianca Fiebig,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Giese, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Dresel, MD,
(1) Ipsen Pharma (2) Merz Pharmaceuticals (3) Zambon
NONE
(1) Pharm Allergan, speaker honoraria (2) Merz Pharmaceuticals, speaker honoraria & travel expenses (3) Abbott, travel expenses (4) Abbvie, travel expenses (5) Desitin, travel expenses
NONE
(1) MR-compatible device for stimulus application, German Patent and Trademark Office 2010
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aikaterini Papagianni, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Birklein, MD, PhD,
Alnylam advisor, ongoing Almirall advisor, ongoing Akcea advisor, ongoing
NONE
NONE
Neurology, ed board, ongoing European Journal of Pain, field editor, ongoing Pain Medidicin, ed board, ongging The Open Neurology Journal, ed board, ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Alnylam, IIT
German Research Foundation 2018-2022 Bi 579/11 Bi579/10
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joachim Weis, MD,
NONE
NONE
(1) Ultragenyx, travel compensation and speaker honorarium
Editorial board member Acta Neuropathologica, Aktuelle Neurologie
NONE
Book editor
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Research Foundation (DFG), applicant, WE 1406/13-1, 2010-2016 (2) DFG, co-applicant, WE 1406/14-3, 2011-2019 (3) DFG, applicant, INST 948/41-1 FUGG, 2018-2019 (4) DFG, applicant, WE 1406/16-1, 2019-2022 (5) German Ministry of Science and Education, MND-Net, applicant, 360644, 2012-2015 (6) German Ministry of Science and Education, CMT-Net, applicant, 01GM1511D, 2015-2019 (7) EU Joint Program Neurodegenerative Disease Research (JPND), applicant, FlySMALS, 2015-2019
NONE
(1) Initiative Therapieforschung ALS e.V. (2) German Society for Muscle Diseases, DGM
NONE
NONE
NONE
NONE
NONE
NONE
- Tessa Huchtemann, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Schmidt, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Körtvelyessy, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carmen Villmann, PhD,
NONE
NONE
NONE
Associate editor - Frontiers in Molecular Neuroscience Associate editor - Biological Chemistry
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Edgar Meinl, MD,
NONE
NONE
(1) Roche, Honorarium (2) Novartis, Honorarium (3) Sanofi, Honorarium (4) Biogen, Honorarium (5) Bioeq, Honorarium
(1) Journal of Pathology, Editorial board, since 2010 (2) Plos One, editor, since 2014 (3) Journal of Biological Chemistry, reviewing editor, since 2015 (4) Frontiers in Immunology, Frontiers in Neurology, associate editor, since 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Sanofi (3) Merck
(1) DFG, SFB TRR 128 (2) BMBF, KKNMS
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Sommer, MD, PhD,
Air Liquide, Alnylam, CSL Behring Pfizer, Sanofi-Genzyme Shire UCB
NONE
CSL Behring Genzyme Grifols Kedrion Pfizer Inc Shire
Academic Editor, PlosOne
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG)328/9-1; 328/10-1 Bundesministerium f?r Bildung und Forschung (BMBF), CMT-Net
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD* and
(1) Roche, Biogen
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Roche (6) Novartis (7) Merck (8) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Doppler, MD*
NONE
NONE
honoraria for educational lectures from Baxalta
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Kedrion
(1)German Research Foundation, DO 2219/1-1, 2018-2021 (2)Federal Ministry of Education and Research (BMBF), 2016-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (H.S., A.M.B., L.A., B.F., A.P., C.S., K.D.), University Hospital Würzburg; Institute of Clinical Neuroimmunology (A.V., E.M.), Biomedical Center, University Hospitals, Ludwig-Maximilians-Universität München, Planegg-Martinsried; Universitätsklinikum Schleswig-Holstein Campus Kiel (A.H., F.L.), Neuroimmunology Section, Institute of Clinical Chemistry, Kiel/Lübeck; Department of Neurology (F.G.), University Hospital Halle; Department of Neurology (C.D., F.B.), University Hospital Mainz, Mainz; University Hospital Aachen (J.W.), Institute of Neuropathology, Aachen; Department of Neurology (T.H., P.K.), University Hospital Magdeburg; Institute for Pharmacology and Toxicology (C.S.), Otto-von-Guericke University; German Center for Neurodegenerative Diseases (P.K.), Magdeburg; Institute for Clinical Neurobiology (C.V.), University Hospital Würzburg; Department of Neurology (F.L.), Universitätsklinikum Schleswig-Holstein, Kiel, Germany; and Research Center for Translational Medicine (A.V), Koç University, Istanbul, Turkey.
- Correspondence
Dr. Doppler Doppler_K{at}ukw.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathyLuise Appeltshauser, Anna-Michelle Brunder, Annika Heinius et al.Neurology: Neuroimmunology & Neuroinflammation, July 24, 2020 -
Article
Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIgLuis Querol, Gisela Nogales-Gadea, Ricardo Rojas-Garcia et al.Neurology, February 12, 2014 -
Article
Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDPClinical relevance of IgG isotypeAndrea Cortese, Raffaella Lombardi, Chiara Briani et al.Neurology: Neuroimmunology & Neuroinflammation, November 21, 2019 -
Null Hypothesis
Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus SyndromeMar Petit-Pedrol, Mar Guasp, Thais Armangue et al.Neurology, December 21, 2020